Rafferty Asset Management, LLC Prometheus Biosciences, Inc. Transaction History

Rafferty Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	SELL	$103.46 - $126.29 $1.42 Million - $1.73 Million	-13,725 Reduced 18.75%	59,464 $6.38 Million
Q4 2022 Feb 13, 2023	SELL	$36.06 - $117.21 $787,658 - $2.56 Million	-21,843 Reduced 22.98%	73,189 $8.05 Million
Q3 2022 Nov 14, 2022	BUY	$28.17 - $59.01 $2.68 Million - $5.61 Million	95,032 New	95,032 $5.61 Million
Q2 2022 Aug 12, 2022	SELL	$22.39 - $38.94 $982,025 - $1.71 Million	-43,860 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$30.13 - $50.0 $1.32 Million - $2.19 Million	43,860 New	43,860 $1.66 Million

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Rafferty Asset Management, LLC with notifications on news.